Journal
CURRENT TREATMENT OPTIONS IN NEUROLOGY
Volume 18, Issue 1, Pages -Publisher
CURRENT MEDICINE GROUP
DOI: 10.1007/s11940-015-0387-9
Keywords
Neuromyelitis optica spectrum disorder; Immunosuppression; Azathioprine; Mycophenolate; Rituximab; Eculizumab
Categories
Funding
- NINDS [NS078555]
Ask authors/readers for more resources
Neuromyelitis optica spectrum disorder (NMOSD) is a rare, autoimmune disease of the central nervous system that primarily attacks the optic nerves and spinal cord leading to blindness and paralysis. The spectrum of the disease has expanded based on the specificity of the autoimmune response to the aquaporin-4 water channel on astrocytes. With wider recognition of NMOSD, a standard of care for treatment of this condition has condition based on a growing series of retrospective and prospective studies. This review covers the present state of the field in the treatment of acute relapses, preventive approaches, and therapies for symptoms of NMOSD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available